The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).
Nicolas Penel
Research Funding - Roche
Jean-Yves Blay
No relevant relationships to disclose
Olivier Mir
No relevant relationships to disclose
Emmanuelle Tresch
No relevant relationships to disclose
Emmanuelle Bompas
No relevant relationships to disclose
Julien Domont
No relevant relationships to disclose
Philippe Alexandre Cassier
No relevant relationships to disclose
Frederic Rolland
No relevant relationships to disclose
Sophie Piperno-Neumann
No relevant relationships to disclose
Antoine Italiano
No relevant relationships to disclose
Christine Chevreau
No relevant relationships to disclose
Didier Cupissol
No relevant relationships to disclose
Jacques-Olivier Bay
No relevant relationships to disclose
Olivier Collard
No relevant relationships to disclose
Esma Saada
No relevant relationships to disclose
François Bertucci
No relevant relationships to disclose
Nicolas Isambert
No relevant relationships to disclose
Corinne Delcambre
No relevant relationships to disclose
Stephanie Clisant
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
No relevant relationships to disclose